Actively Recruiting
Phase 2 Study Comparing Neoadjuvant Nivolumab Plus Relatlimab Opdualag Versus Nivolumab Alone for Treating High-Risk Resectable Basal Cell Carcinoma
Led by University of California, San Diego · Updated on 2026-07-28
30
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a treatment approach for patients with resectable high-risk basal cell carcinoma HR BCC, a type of skin cancer. This Phase 2 clinical trial compares two neoadjuvant therapies given before surgery a combination of Nivolumab plus Relatlimab Opdualag versus Nivolumab alone. The goal is to understand how these treatments affect tumor response and surgical outcomes in this patient group. Participants receive four cycles of either Nivolumab plus Relatlimab or Nivolumab alone, administered intravenously every four weeks before surgery. If the disease progresses early, patients may proceed to surgery after only two cycles. Those showing ongoing benefit may continue treatment beyond four cycles, and some patients with complete clinical response might avoid surgery based on the investigators assessment. Treatment doses are Nivolumab 480 mg plus Relatlimab 160 mg or Nivolumab 480 mg alone, given in 28-day cycles. During the study, participants undergo surgical tumor removal after neoadjuvant therapy. Researchers assess the pathologic response rate at surgery and monitor patients for disease recurrence and clinical complete response over two years. Various clinical evaluations, including physical exams and laboratory tests, are performed to track treatment effects and patient safety throughout the trial period.
CONDITIONS
Brief Title
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Research Team
C
Catherine O'Neil, BS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here